Australian medical device manufacturer Uscom has boosted manufacturing capacity and restructured its China operation in a first half of the financial year that saw revenue down by about a third.
The Sydney company reported revenue of $960,000 for the half ending in December in sales of its range of non-invasive devices.
The China subsidiary was restructured as the company commissioned its first China subsidiary to handle first imports of its devices direct into China.
The company received new China National Medical Products Administration approvals and re-signed distribution contracts with increased margins and volumes.
However the changes delayed first half sales.
During the half the company employed another 28 sales agents in the US, and received Chinese endorsement for its products to be used to monitor coronavirus.
In 2019 Uscom boosted manufacturing capacity in Europe and Australia to ensure supply of its BP+ blood pressure monitor and SpiroSonic digital ultrasonic spirometers for pulmonary function testing.
It also re-structured Uscom Kft, its wholly owned Budapest operation, to meet the anticipated demand from China for SpiroSonic devices.
Uscom’s original product is USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound (pictured).
Uscom chairman Rob Phillips said Uscom science continued to be respected worldwide and be accepted for new uses, such a sepsis and coronavirus.
Phillips said: “Operationally our significant restructure of sales and markeging strategies across China, Europe and the US is beginning to generate results and significant incoming cash.
“…We are reviewing our operating strategies and plan on shifting manufacturing into top gear to meet anticipated demand.”
Subscribe to our free @AuManufacturing newsletter here.